Dyno's Eric Kelsic fills the tank in his quest for better AAV with a group of big-name supporters on board
Adeno-associated viruses (AAV) for gene therapy have received a ton of scrutiny throughout the field’s history after a smattering of safety scares and their limited therapeutic range. Hoping to crack the field wide open through a capsid design revolution, Eric Kelsic and his team at Dyno have drummed up immense excitement — and now a hefty war chest.
Dyno Therapeutics has bagged a $100 million Series A with backing from the likes of round leader Andreessen Horowitz and new investor Casdin Capital in its quest to use AI to design better AAV capsids for gene therapy, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
